Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Peyrin-Biroulet, L, Sandborn, W, Sands, B, Reinisch, W, Bemelman, W, Bryant, R, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, P, Loftus, E, Marteau, P, Munkholm, P, Murdoch, T, Ordás, I, Panaccione, R, Riddell, R, Ruel, J, Rubin, D, Samaan, M, Siegel, C, Silverberg, MS, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, J
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Nature Publishing Group 2015

Παρόμοια τεκμήρια

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
ανά: Sandborn, W, κ.ά.
Έκδοση: (2016)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
ανά: Peyrin-Biroulet, L, κ.ά.
Έκδοση: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
ανά: Danese, S, κ.ά.
Έκδοση: (2015)

Development of an index to define overall disease severity in IBD
ανά: Siegel, C, κ.ά.
Έκδοση: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
ανά: D'Haens, G, κ.ά.
Έκδοση: (2009)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
ανά: Remo Panaccione, κ.ά.
Έκδοση: (2015-12-01)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
ανά: Jairath, V, κ.ά.
Έκδοση: (2016)

Development of the Crohn's disease digestive damage score, the Lemann score.
ανά: Pariente, B, κ.ά.
Έκδοση: (2011)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
ανά: Reinisch, W, κ.ά.
Έκδοση: (2018)

Evolving concepts in phases I and II drug development for Crohn's Disease
ανά: Jairath, V, κ.ά.
Έκδοση: (2016)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
ανά: Khanna, R, κ.ά.
Έκδοση: (2023)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
ανά: Travis, S, κ.ά.
Έκδοση: (2013)

Biosimilars in IBD: hope or expectation?
ανά: Gecse, K, κ.ά.
Έκδοση: (2013)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
ανά: Vuitton, L, κ.ά.
Έκδοση: (2017)

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
ανά: Clark, M, κ.ά.
Έκδοση: (2007)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
ανά: Gasche, C, κ.ά.
Έκδοση: (2000)

Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
ανά: Travis, S, κ.ά.
Έκδοση: (2013)

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].
ανά: Travis, S, κ.ά.
Έκδοση: (2015)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
ανά: Panaccione, R, κ.ά.
Έκδοση: (2019)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
ανά: Travis, S, κ.ά.
Έκδοση: (2012)

Review article: defining remission in ulcerative colitis.
ανά: Travis, S, κ.ά.
Έκδοση: (2011)

European evidence-based Consensus on the management of ulcerative colitis: Current management.
ανά: Travis, S, κ.ά.
Έκδοση: (2008)

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
ανά: Laurent Peyrin-Biroulet, κ.ά.
Έκδοση: (2024-01-01)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
ανά: Sandborn, W, κ.ά.
Έκδοση: (2015)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
ανά: Colombel, J, κ.ά.
Έκδοση: (2017)

CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease
ανά: Ma, C, κ.ά.
Έκδοση: (2022)

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
ανά: Travis, S, κ.ά.
Έκδοση: (2017)

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
ανά: Travis, S, κ.ά.
Έκδοση: (2017)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
ανά: D'Haens, G, κ.ά.
Έκδοση: (2011)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
ανά: Van Assche, G, κ.ά.
Έκδοση: (2011)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
ανά: Travis, S, κ.ά.
Έκδοση: (2014)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
ανά: Lichtenstein, G, κ.ά.
Έκδοση: (2015)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
ανά: D'Haens, G, κ.ά.
Έκδοση: (2018)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
ανά: Yzet, C, κ.ά.
Έκδοση: (2019)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
ανά: Gottlieb, K, κ.ά.
Έκδοση: (2015)

The real-world global use of patient-reported outcomes for the care of patients with inflammatory bowel disease
ανά: Horrigan, JM, κ.ά.
Έκδοση: (2023)

Benzimidazoles promote anti-TNF mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model
ανά: Wildenberg, M, κ.ά.
Έκδοση: (2017)

Antieosinophil Therapeutics
ανά: Straumann, A, κ.ά.
Έκδοση: (2013)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
ανά: Samaan, MA, κ.ά.
Έκδοση: (2018)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
ανά: Travis, S, κ.ά.
Έκδοση: (2017)